(VIANEWS) – Credicorp Ltd. (BAP), Core Laboratories N.V. (CLB), Haemonetics Corporation (HAE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Credicorp Ltd. (BAP)
23.7% sales growth and 16.76% return on equity
Credicorp Ltd., a financial services holding company, provides various financial, insurance, and health services and products primarily in Peru and internationally. The company's Universal Banking segment offers deposits and current accounts, and various credits and financial instruments to individuals and legal entities. Its Insurance and Pensions segment issues insurance policies to cover losses in commercial property, transportation, marine vessels, automobile, life, health, and pensions, as well as provides private pension fund management services. The company's Microfinance segment manages loans, credits, deposits, and current accounts of the small and microenterprises. Its Investment Banking and Wealth Management segment offers its services to corporations, institutional investors, governments, and foundations; engages in structuring and placement of issues in the primary market, as well as the execution and negotiation of operations in the secondary market; and structures securitization processes for corporate customers and manages mutual funds. The company was founded in 1889 and is headquartered in Lima, Peru.
Earnings Per Share
As for profitability, Credicorp Ltd. has a trailing twelve months EPS of $15.03.
PE Ratio
Credicorp Ltd. has a trailing twelve months price to earnings ratio of 8.27. Meaning, the purchaser of the share is investing $8.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.76%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 18, 2022, the estimated forward annual dividend rate is 3.99 and the estimated forward annual dividend yield is 3.21%.
Moving Average
Credicorp Ltd.’s value is below its 50-day moving average of $133.05 and under its 200-day moving average of $133.98.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.4%, now sitting on 15.48B for the twelve trailing months.
2. Core Laboratories N.V. (CLB)
10.7% sales growth and 11.23% return on equity
Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and petroleum products; and proprietary and joint industry studies. The Production Enhancement segment offers services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories N.V. was founded in 1936 and is based in Amstelveen, the Netherlands.
Earnings Per Share
As for profitability, Core Laboratories N.V. has a trailing twelve months EPS of $0.42.
PE Ratio
Core Laboratories N.V. has a trailing twelve months price to earnings ratio of 56.5. Meaning, the purchaser of the share is investing $56.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.23%.
Volume
Today’s last reported volume for Core Laboratories N.V. is 642065 which is 90.74% above its average volume of 336605.
Yearly Top and Bottom Value
Core Laboratories N.V.’s stock is valued at $23.90 at 01:22 EST, way below its 52-week high of $34.18 and way higher than its 52-week low of $13.19.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 112.5% and 83.3%, respectively.
Sales Growth
Core Laboratories N.V.’s sales growth is 10.8% for the present quarter and 10.7% for the next.
3. Haemonetics Corporation (HAE)
8.9% sales growth and 12.71% return on equity
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Haemonetics Corporation has a trailing twelve months EPS of $1.83.
PE Ratio
Haemonetics Corporation has a trailing twelve months price to earnings ratio of 41.17. Meaning, the purchaser of the share is investing $41.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.71%.
Sales Growth
Haemonetics Corporation’s sales growth is 9.3% for the ongoing quarter and 8.9% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 7.7% and 19%, respectively.
Previous days news about Haemonetics Corporation(HAE)
- According to Zacks on Friday, 24 March, "Some other top-ranked stocks in the overall healthcare sector are Haemonetics Corporation (HAE Quick QuoteHAE – Free Report) , Catalyst Pharmaceuticals (CPRX Quick QuoteCPRX – Free Report) and Avanos Medical (AVNS Quick QuoteAVNS – Free Report) . "
- According to Zacks on Friday, 24 March, "Some better-ranked stocks in the overall healthcare sector are Haemonetics Corporation (HAE Quick QuoteHAE – Free Report) , Catalyst Pharmaceuticals (CPRX Quick QuoteCPRX – Free Report) and Avanos Medical (AVNS Quick QuoteAVNS – Free Report) . "
4. Marathon Oil (MRO)
8.1% sales growth and 33.99% return on equity
Marathon Oil Corporation operates as an independent exploration and production company in the United States and internationally. The company engages in the exploration, production, and marketing of crude oil and condensate, natural gas liquids, and natural gas; and the production and marketing of products manufactured from natural gas, such as liquefied natural gas and methanol. It also owns and operates 32 central gathering and treating facilities; and the Sugarloaf gathering system, a 42-mile natural gas pipeline through Karnes and Atascosa Counties. The company was formerly known as USX Corporation and changed its name to Marathon Oil Corporation in December 2001. Marathon Oil Corporation was founded in 1887 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Marathon Oil has a trailing twelve months EPS of $-1.83.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.99%.
Volume
Today’s last reported volume for Marathon Oil is 7707670 which is 25.38% below its average volume of 10330100.
Moving Average
Marathon Oil’s value is way under its 50-day moving average of $25.66 and way below its 200-day moving average of $26.13.
Yearly Top and Bottom Value
Marathon Oil’s stock is valued at $22.08 at 01:22 EST, way below its 52-week high of $33.42 and way above its 52-week low of $19.42.
5. Getty Realty Corporation (GTY)
5.4% sales growth and 11.97% return on equity
Getty Realty Corp. is the leading publicly traded real estate investment trust in the United States specializing in the ownership, leasing and financing of convenience store and gasoline station properties. As of September 30, 2020, the Company owned 896 properties and leased 58 properties from third-party landlords in 35 states across the United States and Washington, D.C.
Earnings Per Share
As for profitability, Getty Realty Corporation has a trailing twelve months EPS of $1.88.
PE Ratio
Getty Realty Corporation has a trailing twelve months price to earnings ratio of 18.37. Meaning, the purchaser of the share is investing $18.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
